about the company
GlaxoSmithKline Consumer Nigeria has historically marketed pharmaceutical products (Augmentin, Panadol) and consumer healthcare brands (Sensodyne, Lucozade, Ribena) in Nigeria. In 2023 GSK announced its exit from direct commercial operations in Nigeria, transitioning to a third-p…
research, on demand
Follow-up Q&A grounded in this page: price, AI take, research note, recent news, and sector peers. Anonymous, with a daily question cap. Answers are introductory context, not advice.
Sign in to generate research on GLAXOSMITH — Vantis reads the filings, financials, news, and insider activity, and returns a sourced read in about a minute.
| Ex-date | Pay date | Type | Amount |
|---|---|---|---|
| 05 May 2023 | — | final | ₦0.55NGN |
| 25 Apr 2022 | — | final | ₦0.45NGN |
| 26 Apr 2021 | — | final | ₦0.40NGN |
| 23 Jun 2020 | — | final | ₦0.55NGN |
| 24 Apr 2019 | — | final | ₦0.50NGN |
| 24 Apr 2018 | — | final | ₦0.40NGN |
| 13 Apr 2017 | — | final | ₦0.30NGN |
| 04 Oct 2016 | — | final | ₦0.60NGN |
NGN cash dividends are paid net of 10% withholding tax· Source: corporate-actions market data
No NGX corporate disclosures on record for GLAXOSMITH. New filings appear here shortly after they're published on the exchange.
No director or insider dealing notices on record for GLAXOSMITH. New notices appear here shortly after they're filed on the exchange.
No news for this ticker.
